Comparison of Nutritional Products for People With Type 2 Diabetes

Inclusion criteria

• Subject states that he/she has type 2 diabetes (as evidenced by use of oral hypoglycemic medication for at least two months).
• Subject is between 18 and 75 years of age, inclusive.
• Subject is a male or a non-pregnant, non-lactating female, at least 6 weeks postpartum prior to screening visit.
• If female is of childbearing potential, is practicing a method of birth control.
• Subject's BMI is > 18.5 kg/m2 and < 35 kg/m2.
• If on a chronic medication such as anti-hypertensive, lipid-lowering, thyroid medication or hormone therapy, subject has been on constant dosage for at least two months prior to screening visit.

Exclusion criteria

• Subject uses exogenous insulin for glucose control.
• Subject states that he/she has type 1 diabetes.
• Subject states that he/she has a history of diabetic ketoacidosis.
• Subject takes an alpha-glucosidase inhibitor.
• Subject states that he/she has a current infection ; has had inpatient surgery, or corticosteroid treatment in the last 3 months or antibiotics in the last 3 weeks prior to screening visit.
• Subject states that he/she has an active malignancy (excluding the following dermal malignancies: basal cell carcinoma, squamous cell carcinoma, carcinoma in-situ of the cervix).
• Subject states that he/she has had a significant cardiovascular event ≤ six months prior to screening visit; or stated history of congestive heart failure.
• Subject states that he/she has end stage organ failure or is status post organ transplant.
• Subject states that he/she has a history of renal disease.
• Subject states that he/she has current hepatic disease.
• Subject states that he/she has a history of severe gastroparesis.
• Subject states that he/she has a chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV.
• Subject has taken/is currently taking any herbals, dietary supplements, or medications, other than oral hypoglycemic medications, during the past four weeks prior to screening visit that could profoundly affect blood glucose.
• Subject states that he/she has clotting or bleeding disorders.
• Subject is known to be allergic or intolerant to any ingredient found in the study products.